GlassScriptPhysician profile
M David Lauter
NPI 1366544819
$21,437.93
in general payments reported to CMS, 2019-2025
57 companies · $2,983 in 2025
The $2,983 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,628 · 2020: $2,406 · 2021: $3,815 · 2022: $2,696 · 2023: $2,777 · 2024: $3,133 · 2025: $2,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,820 · Education: $72.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,819.53 |
| Education | $72.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,501.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,373.68 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,870.75 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Glaxosmithkline, LLC. | $1,804.84 | 2019-2025 | Trelegy Ellipta, Nucala |
| Pfizer INC. | $1,206.23 | 2019-2025 | |
| Amgen INC. | $1,088.28 | 2019-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $975.36 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Novo Nordisk INC | $880.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $809.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $765.63 | 2019-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $627.08 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $498.46 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $438.29 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $436.85 | 2019-2025 | Spravato, Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $320.31 | 2020-2025 | Trintellix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Lauter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.